Skip to content

Join Us
Members Area

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Publication Category: Medications

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial

I. Lingvay; A. M. Catarig; J. P. Frias; H. Kumar; N. L. Lausvig; C. W. le Roux; D. Thielke; A. Viljoen; R. J. McCrimmon Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial The Lancet Diabetes and Endocrinology
Insulin Resistance & Diabetes

Weight loss outcomes with semaglutide 2.4 mg in moderate or severe obesity in step 1 and 2

C. Le Roux; A. Aminian; R. Batterham; D. Hesse; C. Jensen; B. McGowan; A. Pakseresht; G. Rigas Sydney; F. Rubino; S. Taheri; et al. Weight loss outcomes with semaglutide 2.4 mg in moderate or severe obesity in step 1 and 2 Obesity (Silver Spring, Md.)
Insulin Resistance & Diabetes

Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m2: A Post-hoc Analysis

C. Le Roux; V. Aroda; J. Hemmingsson; A. P. Cancino; R. Christensen; X. Pi-Sunyer Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m2: A Post-hoc Analysis Obesity Facts
Insulin Resistance & Diabetes

Liraglutide 3.0 mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the scale obesity and prediabetes randomized, double-blind, placebo-controlled 56-week trial

C. Le Roux; A. Astrup; K. Fujioka; F. L. Greenway; A. Halpern; M. Krempf; D. C. Lau; R. V. Ortiz; J. Wilding; C. B. Jensen; et al. Liraglutide 3.0 mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: the scale obesity and prediabetes randomized, double-blind, placebo-controlled 56-week trial Endocrine reviews. Conference: 96th annual meeting and expo of the endocrine society, ENDO 2014. Chicago, IL united states. Conference start: 20140621. Conference end: 20140624. Conference publication: (var.pagings)

Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial

C. Le Roux; D. C. W. Lau; A. Astrup; K. Fujioka; F. Greenway; A. Halpern; M. Krempf; R. Violante Ortiz; J. P. H. Wilding; C. B. Jensen; et al. Safety and tolerability of liraglutide 3.0 mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial Diabetologia

Early responders to liraglutide 3.0mg as adjunct to diet and exercise from the SCALE

C. W. Le Roux; S. Wharton; S. K. Lilleore; C. H. Jepsen; L. J. Aronne Early responders to liraglutide 3.0mg as adjunct to diet and exercise from the SCALE Diabetic medicine

Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors: SCALE obesity and prediabetes randomised, double-blind, placebo-controlled 3-year trial

C. W. Le Roux; A. Astrup; F. Greenway; M. Krempf; R. Vettor; L. Shapiro Manning; S. K. Lilleore; K. Fujioka Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors: SCALE obesity and prediabetes randomised, double-blind, placebo-controlled 3-year trial Diabetologia
Insulin Resistance & Diabetes

Once-weekly semaglutide 2.4 mg improved metabolic syndrome in adults with overweight or obesity: post-hoc analysis of the STEP 1 Trial

C. W. Le Roux; M. Davies; J. P. Frias; P. N. Laursen; I. Lingvay; S. Machineni; A. Varbo; J. P. Wilding; S. O. Wallenstein; L. Perreault Once-weekly semaglutide 2.4 mg improved metabolic syndrome in adults with overweight or obesity: post-hoc analysis of the STEP 1 Trial Obesity facts
Metabolic Syndrome

Early weight loss responders to liraglutide 3.0mg had greater weight loss, regression to normoglycaemia, and reduced Type 2 diabetes development at three years vs early non-responders: SCALE Obesity and Prediabetes

C. W. Le Roux; D. C. W. Lau; K. Fujioka; F. Greenway; J. P. H. Wilding; P. B. Jacobsen; T. Skjoth; S. Madsbad Early weight loss responders to liraglutide 3.0mg had greater weight loss, regression to normoglycaemia, and reduced Type 2 diabetes development at three years vs early non-responders: SCALE Obesity and Prediabetes Diabetic medicine
Insulin Resistance & Diabetes

Liraglutide; A new hope for obese diabetics

A. Kumar; D. Kumar; S. Razzaque; A. Kumar; R. Kumar; M. I. Ghauri; M. Yaseen Liraglutide; A new hope for obese diabetics Journal of the Liaquat University of Medical and Health Sciences
Insulin Resistance & Diabetes

Older posts

Newer posts

← Previous Page1 … Page11 Page12 Page13 … Page18 Next →

Search for:

Recent Posts

9th ASOI Annual Conference – Registration now open!
Press Release for World Obesity Day 4th March 2024
ASOI and ICPO response to : Medical Council Communication: “Important medicine shortage information – Ozempic (semaglutide)”
Things to do in Dublin during ECO
ECO 2023 sponsorship update

ASOI

info@asoi.info

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Menu

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Privacy Policy
Site Map

©2024 ASOI